Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;38(1):561-575.
doi: 10.1080/02656736.2021.1905189.

Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound

Affiliations

Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound

Zhen Xu et al. Int J Hyperthermia. 2021.

Abstract

Histotripsy is the first noninvasive, non-ionizing, and non-thermal ablation technology guided by real-time imaging. Using focused ultrasound delivered from outside the body, histotripsy mechanically destroys tissue through cavitation, rendering the target into acellular debris. The material in the histotripsy ablation zone is absorbed by the body within 1-2 months, leaving a minimal remnant scar. Histotripsy has also been shown to stimulate an immune response and induce abscopal effects in animal models, which may have positive implications for future cancer treatment. Histotripsy has been investigated for a wide range of applications in preclinical studies, including the treatment of cancer, neurological diseases, and cardiovascular diseases. Three human clinical trials have been undertaken using histotripsy for the treatment of benign prostatic hyperplasia, liver cancer, and calcified valve stenosis. This review provides a comprehensive overview of histotripsy covering the origin, mechanism, bioeffects, parameters, instruments, and the latest results on preclinical and human studies.

Keywords: High intensity ultrasound; imaging; immunotherapy; physics; ultrasound.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
High-speed photograph of cavitation generated by (A) intrinsic threshold histotripsy (modified from ref [69]) and (B) shockscattering histotripsy (modified from ref [73]). Ultrasound propagates from left to right.
Figure 2.
Figure 2.
(A) H&E slide of an ex vivo porcine cardiac tissue treated by histotripsy shows no intact cells within the treated region and bisected cells at the sharp lesion boundary. (B–C) Gross morphology of the rat liver treated by histotripsy shows a darkly colored hematoma within the histotripsy-treated zone right after treatment (B) and only a small contracted scar on Day 28 (C). (D) Histology of the rat liver treated by histotripsy shows a small focus of residual scar and foreign body giant cells (GC) with calcified undigested debris on Day 28. (B–D) are reproduced based on images from ref [22]. (E) A perforation is generated by histotripsy through a piece of ex vivo porcine atrial wall.
Figure 3.
Figure 3.
(A) Large blood vessels remain intact and surrounded by acellular debris within the in vivo porcine liver treated by histotripsy (reproduced based on an image from ref [37]. (B) Contrast-enhanced MR image showing a patent bile duct (blue arrow) within the dark histotripsy treatment zone (reproduced based on an image from ref [84].
Figure 4.
Figure 4.
An ultrasound-guided histotripsy system that contains an ultrasound imaging engine, a histotripsy transducer with the imaging probe in the center (insert), a positioning arm that mechanically moves the histotripsy transducer.
Figure 5.
Figure 5.
(A) Histotripsy-generated cavitation is seen as a hyperechoic zone on B-mode ultrasound. (B) ‘M’ shaped histotripsy lesion shows as a hypoechoic zone on B-mode ultrasound image. (C) Histotripsy ablation zone is seen as a hypointense (non-enhancing) region on this T1-weighted contrast-enhanced MR image.
Figure 6.
Figure 6.
(A–D) Histotripsy treatment in the in vivo porcine liver. Axial T2-weighted MR images (A) and gross morphology (B) show the spherical ablation volume. (C) H&E slide of (100X) of the center of the ablation zone demonstrates no viable hepatocytes. (D) H&E slide (100X) of the periphery of the ablation shows viable liver (L), necrotic liver (N), and a thin zone of transition (Z). (E–G) MR images of partial histotripsy treatment in a rodent HCC model. (E) The appearance of the original untreated tumor on T2-weighted MRI was hyperintense (yellow arrow). (F) Post histotripsy, the ablation zone demonstrates T2 hypointense signal (red dashed lines). (G) At 12 weeks, only a ~5 mm non-tumoral fibrous tissue zone is detectable on MRI at the original tumor site, indicating near-complete resolution of the ablation zone and tumor. (H–I) Histotripsy induced immune response and abscopal effect (reproduction based on images from ref [39]. (H) FACS analysis of histotripsy-ablated (HT ablated) and contralateral non-ablated tumors (HT abscopal) identified comparable levels of intratumoral CD8+ T cell infiltration that is significantly higher than the untreated control tumors. (I) At gross examination, pulmonary metastases were reduced in mice treated with histotripsy compared to untreated controls.

References

    1. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–682. - PubMed
    1. Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44–54. - PubMed
    1. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78(1):113–124. - PubMed
    1. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17(1):171–178. - PubMed
    1. Lanza E, Palussiere J, Buy X, et al. Percutaneous image-guided cryoablation of breast cancer: a systematic review. J Vasc Interv Radiol. 2015;26(11):1652–1657. - PubMed

Publication types